MTOR and B-cell non-Hodgkin lymphoma: Recent research has emphasized that the aberrant expression of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway plays a crucial role in tumor cell proliferation and survival, including B-cell lymphomas [84,85,86].